AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05473429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TSA2 Thermosensory Stimulator
Description: TSA thermal analyzer uses the thresholds for four sub-modalities to measure thermal sensory threshold. This device is capable of heating or cooling the skin as needed to detect heat and cold tolerance and to deliver thermal stimuli.
Study NCT05789602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-460372
Description: Subjects will receive BPI-460372 until disease progression
Study NCT06779344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MxA and CRP feedback
Description: MxA and CRP results will be reported to the attending physcian within 4 hours, along with antimicrobial treatment guidelines based on these results.
Study NCT06779344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization.~Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score).~Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death.
Study NCT06779344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization.~Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score).~Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death.
Study NCT06779032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: PCR method to see leucocyte telomere length
Study NCT06779032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: PCR method to see p16
Study NCT06779565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyflex EDM system
Description: A rotary file system
Study NCT04693598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FBX-101
Description: A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Study NCT05968586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body positioning
Description: Body positioning of infants prone vs supine.
Study NCT05968586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body positioning
Description: Body positioning of infants prone vs supine.
Study NCT05081882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava
Description: Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
Study NCT05081882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants on this arm will take one placebo capsule orally three times daily for 28 days.
Study NCT06553300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autotransplantation with PRF
Description: Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF
Study NCT06553300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autotransplatation Only
Description: Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
Study NCT06779565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reciproc VDW system
Description: A reciprocating file system
Study NCT05605015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTIVE-CR
Description: The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
Study NCT05599815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: ADX-629 (250 milligrams) administered twice daily
Study NCT06030817 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-CNDG SPECT/CT
Description: Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
Study NCT06452069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMMUNO19
Description: 280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time.
Study NCT06452069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IMMUNO19
Description: 280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time.
Study NCT05155618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INTERVENTION GROUP
Description: Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
Study NCT04611958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERCP with Bupivacaine infusion
Description: Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom.
Study NCT04971239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical methotrexate micoemulsion
Description: The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
Study NCT04971239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical methotrexate micoemulsion
Description: The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
Study NCT04971239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer light
Description: the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
Study NCT04971239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B
Description: the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
Study NCT04861818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Description: Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
Study NCT05046990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Regular Arrangement of Collecting Venules
Description: This is a prospective, multicentre, international study without a control group.
Study NCT05129280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7444973
Description: RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
Study NCT05129280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants >/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Study NCT03923452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day.
Study NCT06381700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySmile app
Description: The MySmile app contains several features:~A) Knowledge Hub~1. Do You Know section: This section consists of seven (7) topics where users can learn about oral health knowledge.~2. Quiz time section: In this section, school children can play games and challenge themselves.~B) Track yourself Brushing diary Diet diary~C) Get help~1. Ask an expert~2. Find your dentist~3. Friendly reminders
Study NCT06381700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This will receive the usual School Dental Service.~School Dental Service provide students who need dental treatment and will be called to be given treatment. Among the treatments given include:~* Dental filling~* Full mouth scaling~* Dental extraction~* Preventive treatment, such as topical fluoride application~All treatment is free of charge except for dentures, crown/bridge work and orthodontics. Treatment for school children is based on normative needs assessment as determined by the dentist. A child is defined as orally fit when all required treatment in the SDS has been completed and appropriate oral hygiene status is maintained.
Study NCT05298371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Corrected Sitting postures
Description: Change after being in Corrected Sitting postures
Study NCT05298371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Natural / relaxed sitting postures
Description: Change after being in relaxed sitting postures
Study NCT05298371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Corrected Standing posture
Description: Change after being in Corrected Standing posture
Study NCT05298371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Natural / relaxed standing postures
Description: Change after being in relaxed standing postures
Study NCT06520371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency
Description: For the percutaneous radiofrequency treatment, a medium electrode size will be placed on either side of the knee: one skin electrode on the inside and one on the outside of the knee for 15 minutes.
Study NCT06520371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiofrequency
Description: For the conventional radiofrequency treatment, a 50 Hz sensory stimulation will be performed with a 10 cm, 22 gauge, 10 mm active tip radiofrequency cannula. After receiving the appropriate sensory and motor stimuli, a radiofrequency of 90°C will be applied for 90 s.
Study NCT05762419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide; Oral, 50 Mg
Description: Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m\^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
Study NCT05762419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound with neuro-navigator-controlled sonication
Description: Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
Study NCT06411639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ianalumab
Description: ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.
Study NCT05438823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Programe
Description: IBK-EBP will be administered to parents in six sessions in six days. After six days of training, the mobile application will be used by parents for 8 weeks. The frequency of use of the mobile application will be left entirely to the needs of the parents and reminders will be made through the mobile application. In addition, the video used during the face-to-face training, progressive relaxation exercise videos and motivational sentences will also be included in the mobile application.
Study NCT05206240 — intervention group
Intervention type: OTHER
Intervention: Radial extracorporeal shock wave therapy and conventional physical therapy
Description: The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks.
Study NCT05998070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
Study NCT05598944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The MBSR program
Description: The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead.
Study NCT05598944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Más Presente, the UGRComp program
Description: Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
Study NCT05598944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-muscular stimulation
Description: Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
Study NCT06107842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gerofit exercise
Description: Individualized exercise prescription as well as a group exercise class based on physical function assessments offered 3x/week
Study NCT06107842 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health education
Description: Scheduled monthly in-person health education discussion sessions covering 12 different health topics not including a physical activity/exercise promotion session
Study NCT04739553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His Pacing
Description: The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
Study NCT05093595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SFC
Description: The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
Study NCT05145322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite with 90 degree cavosurface angle
Description: Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
Study NCT05145322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite with wide bevel
Description: Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
Study NCT06205550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide monotherapy
Study NCT06205550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide + beta-blocker
Description: Flecainide + beta-blocker
Study NCT05205850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC118-ADC
Description: RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
Study NCT04916353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic dextrose water
Description: 20% hypertonic dextrose water injection for chronic shoulder pain
Study NCT04916353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide.
Description: Triamcinolone Acetonide 40mg/1ml injection
Study NCT05143840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Potent tyrosine kinase inhibitor that displays anti-tumor activity by specifically targeting the ABL myristate-binding pocket (STAMP).
Study NCT05143840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascimininb + Nilotinib
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of nilotinib 300mg, once daily, with the goal of attaining MR4.5.
Study NCT05143840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib + Imatinib
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of imatinib 300mg, once daily, with the goal of attaining MR4.5.